CAMBRIDGE, Mass .– (BUSINESS WIRE) – Feb.4, 2021–
Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that its board of directors has approved several senior management team promotions , including Gregory Carven, Ph.D. to the Chief Scientific Officer, Junlin Ho, JD, to the General Counsel and Corporate Secretary, and to George Nomikos, MD, Ph.D. to Senior Vice President, Medical and Clinical Sciences, Head of Muscle Therapy.
This press release contains multimedia. The full version can be found here: https://www.businesswire.com/news/home/20210204005942/de/
Gregory Carven, PhD (Photo: Business Wire)
“I am delighted to announce the promotion of these talented leaders who have made a significant contribution to the advancement of our clinical programs, the scientific platform and the overall organization,” said Tony Kingsley, President and CEO of Scholar Rock. “We are well positioned for another year of transformation, as we are pursuing important clinical and preclinical milestones, including 12-month results from our TOPAZ phase 2 study at SMA as well as initial clinical response and safety data from the DRAGON study SRK-181 in Immuno-Oncology. Our commitment to developing and caring for team members continues to be a cornerstone of our business and contributes to our mutual success by advancing therapies to help patients in need. “
Dr. Carven joined Scholar Rock in 2014 and was Vice President of Antibody Discovery and Protein Science before being promoted to SVP in January 2018 and Head of Research in June 2020. Working with the respected executives on our Scientific Advisory Board and Science, Innovation, As CSO, he will lead the discovery, biology and translation business and drive the advancement of our scientific platform. Dr. Carven is a recognized leader with more than 15 years of experience in the discovery and development of antibody therapeutics. He was recognized for inventing Keytruda® (pembrolizumab) when he received an “Inventor of the Year” award from the Intellectual Property Owners Education Foundation in 2016. Before joining Scholar Rock, Dr. Carven hybridoma antibody discovery efforts at Pfizer and held positions of increasing responsibility at Merck Research Laboratories (formerly Schering Plow Research Institute and Organon Biosciences). He received his Ph.D. in biological chemistry from the Massachusetts Institute of Technology and continued his research at the University of Massachusetts Medical School.
Ms. Ho joined Scholar Rock in 2018 and has been Senior Vice President, Head of Legal and Corporate Secretary, since March 2020. As General Counsel, she will oversee all legal matters, including corporate governance, compliance and intellectual property. She has more than 13 years of experience leading and advising life science companies on various legal aspects related to corporate governance, business development, finance, securities law, planning and launching commercial products and international activities. Prior to joining Scholar Rock, Ms. Ho was Associate General Counsel at Foundation Medicine and Associate General Counsel at Ziopharm Oncology. She was previously a corporate attorney in the life sciences practice with the law firm Ropes & Gray LLP. Ms. Ho received her BS from the Massachusetts Institute of Technology and JD from the University of Chicago Law School.
Dr. Nomikos joined Scholar Rock in 2019 as Vice President, Head of Medical Research, Muscle Franchise, and was instrumental in leading the clinical program for apitegromab in spinal muscular atrophy. As SVP, he will be responsible for leading all medical and clinical functions focused on muscle therapeutics. Dr. Nomikos is a physician-scientist with 35 years of academic and industrial experience in neuroscience, neuropharmacology, and central nervous system therapeutics. He received his MD from the University of Athens and Ph.D. in Neuroscience from the Department of Psychiatry at the University of British Columbia. He was an Associate Professor of Neuropharmacology at the Karolinska Institute in Stockholm, Sweden before entering the biopharmaceutical industry. Before joining Scholar Rock, Dr. Nomikos has held various senior scientific and clinical positions and has led global clinical programs and discovery projects at Biogen Inc., Sage Therapeutics, Takeda Pharmaceuticals Company Ltd., Astellas Pharma, Inc., Amgen, Inc. and Eli Lilly and Society.
About Scholar Rock
Scholar Rock is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative drugs for the treatment of serious diseases in which signaling by protein growth factors is essential. Scholar Rock is developing a pipeline of novel product candidates with the potential to change the lives of patients suffering from a variety of serious diseases, including neuromuscular diseases, cancer, fibrosis and anemia. Scholar Rock’s approach to targeting the molecular mechanisms underlying growth factor activation enabled the development of a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target these signaling proteins at the cellular level. By developing product candidates that work in the disease’s microenvironment, the company intends to avoid the historical challenges associated with inhibiting growth factors for therapeutic effect. Scholar Rock believes that its focus on biologically validated growth factors could enable a more efficient development path. For more information, please visit www.ScholarRock.com or follow Scholar Rock on Twitter (@ScholarRock) and LinkedIn (https://www.linkedin.com/company/scholar-rock/).
Scholar Rock® is a registered trademark of Scholar Rock, Inc.
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements regarding the future expectations, plans and prospects of Scholar Rock, including but not limited to Scholar Rock’s expectations regarding it The growth, strategy, progress and timing of its clinical trials for apitegromab, SRK-181 and other product candidates, and timing of indication selection and development, its cash runway, a product candidate’s ability to perform in humans that is comparable to previous non-clinical studies matches preclinical or clinical study data as well as the potential of the product candidates and the proprietary platform. The use of words such as “may”, “could”, “will”, “should”, “expect”, “plan”, “anticipate”, “believe”, “estimate”, “project”, “intend” “future.” “,” Potential “or” continuing “and other similar expressions are intended to identify such forward-looking statements. All these forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied in such forward-looking statements. These risks and uncertainties include Scholar Rock’s ability to provide the financial support, resources and expertise necessary to identify and develop product candidates at the anticipated time, the data obtained from non-clinical and preclinical studies and clinical trials generated by Scholar Rock, as well as competition from third parties developing products for similar purposes, Scholar Rock’s ability to preserve, maintain and protect its intellectual property, the success of Scholar Rock’s current and potential future collaboration, including working with Gilead, Scholar Rock’s reliance on third parties to develop and manufacture product candidates, including providing clinical trials, Scholar Rock’s ability to manage expenses and, if necessary, obtain additional funding to operate its business Support and maintain strategic business alliances and new business initiatives, and the impact of public health pandemics such as COVID-19 on business operations. The expectations and risks set out in the Risk Factors section of Scholar Rock’s Quarterly Report on Form 10- Q for the quarter ended September 30, 2020, as well as the discussion of potential risks, uncertainties, and other important factors in Scholar Rock’s subsequent filings with the Securities and Exchange Commission. All forward-looking statements reflect Scholar Rock’s views as of today only and should not be taken as a representation of its views at any future date. All information in this press release is correct as of the date of publication. Scholar Rock is under no obligation to update this information unless required by law.
View source version on businesswire.com: http://www.businesswire.com/news/home/20210204005942/de/
CONTACT: Scholar Rock Contacts:
[email protected] media
KEYWORD: MASSACHUSETTS UNITED STATES NORTH AMERICA
KEYWORD IN INDUSTRY: PROFESSIONAL SERVICES HEALTH HUMAN RESOURCES CLINICAL STUDIES PHARMACEUTICAL BIOTECHNOLOGY
SOURCE: Scholar Rock
Copyright Business Wire 2021.
PUB: 04.02.2021 4.30 p.m. / DISC: 04.02.2021 4.30 p.m.